Angiotensin II for Post Cardiac Surgery Vasoplegia (ANGII_V)

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-94
SponsorMethodist Healthcare System of San Antonio

About this trial

The goal of this study is to conduct a prospective trial implementing a modified version of the Emory Protocol for administering ANG II to patients with post cardiac bypass vasoplegia. The main questions we aim to answer are: 1.) does administration of improve mortality, 2.) does the administration of Ang II using the modified protocol shorten the time needed to reach optimal MAP, 3.) does the administration of Ang II using the modified protocol shorten length of stay in the ICU and hospital? Researchers will compare outcomes from the interventional group to historical controls who did not receive Ang II using the modified protocol.

Eligibility criteria

Qualifiers

Provision of signed and dated informed consent form

Stated willingness to comply with all study procedures and availability for the duration of the study

Male or female, aged 18 or over

Exhibiting vasoplegia or vasoplegic shock following surgeries involving cardiopulmonary bypass

Disqualifiers

Current use of angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs)

Presence of treatment with high-dose glucocorticoids

Pregnancy or lactation

Known allergic reactions to components of the Giapreza, <specify components/allergens>

Trial design

Treatments tested in this trial

  • Angiotensin II (Giapreza®)

Treatment groups

329 Participants
are divided into 2 treatment groups

Locations

This trial has no locations